Antibodies News and Research

RSS

Study provides important insights into early stages of SARS-CoV-2 infection

Researchers in the UK have provided important new insights into the early stages of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

30 Jun 2021

Intranasal COVID-19 vaccine developed from bacterial extracellular vesicle induces robust antibody response in preclinical trials

A team of US-based scientists recently developed a novel vaccine candidate against SARS-CoV-2, the causative pathogen of COVID-19. The vaccine is composed of extracellular vesicles of Salmonella typhimurium incorporated with the spike receptor-binding domain (RBD) of SARS-CoV-2. Upon intranasal administration in hamsters, the vaccine induces strong blood antibody titers and protects against severe COVID-19.

30 Jun 2021

Is the SARS-CoV-2 delta variant threatening vaccine efficacy?

A new study in the UK, by researchers at Imperial College London, The Francis Crick Institute and the University of Glasgow, explores the loss of coronavirus disease 2019 (COVID-19) vaccine efficacy against the virus behind the current pandemic caused by the emergence of newer variants that have undergone mutational escape.

30 Jun 2021

Assessing the safety of inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents

New clinical trial data, recently published in The Lancet’s Infectious Diseases, presents an initial report on the effect of an inactivated SARS-CoV-2 vaccine, CoronaVac, on children and adolescents from ages 3-17 in a double-blind, randomized setting.

30 Jun 2021

New method to transport RNA-based drugs to subpopulation of immune cells

Tel Aviv University's groundbreaking technology may revolutionize the treatment of cancer and a wide range of diseases and medical conditions. In the framework of this study, the researchers were able to create a new method of transporting RNA-based drugs to a subpopulation of immune cells involved in the inflammation process, and target the disease-inflamed cell without causing damage to other cells.

30 Jun 2021

NIH-funded adjuvant improves the efficacy India's COVID-19 vaccine

An adjuvant developed with funding from the National Institutes of Health has contributed to the success of the highly efficacious COVAXIN COVID-19 vaccine, which roughly 25 million people have received to date in India and elsewhere.

30 Jun 2021

Widespread SARS-CoV-2 mutation escapes vaccine- and infection-induced CD8 T-cell responses

Researchers in the UK have warned that a widespread mutation that has arisen in the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) appears to escape recognition by CD8 T-cell responses in both convalescent patients and recipients of the current coronavirus disease 2019 (COVID-19) vaccines.

29 Jun 2021

Six antibody features could be used to identify women at risk of placental malaria

Six antibody characteristics could help scientists identify which pregnant women are at risk of placental malaria infections, finds a study published today in eLife.

29 Jun 2021

More evidence that mixing COVID-19 vaccines may help elicit a robust immune response

Eight volunteers who received a complete dose or a single dose of an mRNA vaccine or the ChAdOx1 vaccine after a dose of a trial gorilla adenovirus vaccine showed a significantly high level of antibodies and T cell response against SARS-CoV-2.

29 Jun 2021

New spider web mechanism kills pathogens and virus responsible for COVID-19

Immunologists at McMaster University have discovered a previously unknown mechanism which acts like a spider web, trapping and killing pathogens such as influenza or SARS-CoV-2, the virus responsible for COVID-19.

29 Jun 2021

H69/V70 deletion in Alpha variant enables SARS-CoV-2 to overcome chinks in its armor

One of the key mutations seen in the 'Alpha variant' of SARS-CoV-2 - the deletion of two amino acids, H69/V70 - enables the virus to overcome chinks in its armor as it evolves, say an international team of scientists.

29 Jun 2021

Immune response to FDA-approved vaccines is strong and potentially long-lasting

The first two COVID-19 vaccines authorized for emergency use by the Food and Drug Administration (FDA) employed a technology that had never before been used in FDA-approved vaccines.

29 Jun 2021

What's behind COVID-19 vaccine side effects?

A growing concern among coronavirus vaccines is the vaccine side effects. Fear or misinformation about side effects may fuel vaccine hesitancy, contributing to low vaccination rates. Australian researchers recently published an article in Science Immunology to discuss why people develop side effects and their benefits.

28 Jun 2021

Differences in monocyte subsets between severe COVID-19 and long COVID

Researchers in the United States and Costa Rica have identified differences in the proportions of monocyte subsets that occur in severe cases of coronavirus disease 2019 (COVID-19) following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and post-acute sequelae of COVID-19 (PASC), often referred to as “Long COVID”.

28 Jun 2021

Blood cancer patients show widely variable response to COVID-19 vaccines

Patients with a type of blood cancer called multiple myeloma had a widely variable response to COVID-19 vaccines--in some cases, no detectable response--pointing to the need for antibody testing and precautions for these patients after vaccination, according to a study that will be published in Cancer Cell this week.

28 Jun 2021

Could the activation of FcγRIII/CD16 by anti-spike SARS-CoV-2 antibodies independently determine COVID-19 severity?

A team of scientists from Germany recently investigated whether hyperactivation of immune receptors that recognize the Fc part of an IgG molecule (FcγR) can lead to immunopathologic changes in coronavirus disease 2019 (COVID-19) patients. They have observed that hyperactivation of FcγRIII (CD16) by proinflammatory IgG antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can significantly contribute to COVID-19 related immunopathology.

28 Jun 2021

UK study finds SARS-CoV-2 antibodies in domestic cats and dogs

Researchers analyzed sera from pet cats and dogs and found them to have developed antibodies against the virus later on during the COVID-19 pandemic. These findings suggest that viral prevalence among the human populations could have led to the pets becoming infected.

28 Jun 2021

Study associates higher antibody titers with naïve B cells post-mRNA vaccination

Researchers compared peripheral blood mononuclear cells in people with high and low antibody titers after two doses of the Pfizer/BioNTech (BNT162b2) mRNA vaccine. They found a positive correlation between naïve B cells present before vaccination and high antibody titers.

28 Jun 2021

Vaccines and drugs must be adapted to combat emerging SARS-CoV-2 variants, says study

A new review of the emerging variants of concern (VOCs) of the SARS-CoV-2, which has caused the COVID-19 pandemic, shows that there is a major need to constantly re-evaluate the utility of existing therapeutics and vaccines against the virus and to develop new ones.

28 Jun 2021

Tocilizumab and sarilumab shown to be effective in critical COVID-19

A new study, released as a preprint on the medRxiv* server, describes how a team of researchers from the University Medical Center Utrecht in the Netherlands explored the efficacy of four monoclonal antibodies that antagonize powerful pro-inflammatory pathways. The team sought to determine which were useful in treating critically ill COVID-19 patients on organ support.

28 Jun 2021

Antibodies News and Research

Study provides important insights into early stages of SARS-CoV-2 infection

Intranasal COVID-19 vaccine developed from bacterial extracellular vesicle induces robust antibody response in preclinical trials

Is the SARS-CoV-2 delta variant threatening vaccine efficacy?

Assessing the safety of inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents

New method to transport RNA-based drugs to subpopulation of immune cells

NIH-funded adjuvant improves the efficacy India's COVID-19 vaccine

Widespread SARS-CoV-2 mutation escapes vaccine- and infection-induced CD8 T-cell responses

Six antibody features could be used to identify women at risk of placental malaria

More evidence that mixing COVID-19 vaccines may help elicit a robust immune response

New spider web mechanism kills pathogens and virus responsible for COVID-19

H69/V70 deletion in Alpha variant enables SARS-CoV-2 to overcome chinks in its armor

Immune response to FDA-approved vaccines is strong and potentially long-lasting

What's behind COVID-19 vaccine side effects?

Differences in monocyte subsets between severe COVID-19 and long COVID

Blood cancer patients show widely variable response to COVID-19 vaccines

Could the activation of FcγRIII/CD16 by anti-spike SARS-CoV-2 antibodies independently determine COVID-19 severity?

UK study finds SARS-CoV-2 antibodies in domestic cats and dogs

Study associates higher antibody titers with naïve B cells post-mRNA vaccination

Vaccines and drugs must be adapted to combat emerging SARS-CoV-2 variants, says study

Tocilizumab and sarilumab shown to be effective in critical COVID-19

Antibodies eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest Life Science News